<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5A24FD58-D7D3-418E-BE01-3425AD8F9D43"><gtr:id>5A24FD58-D7D3-418E-BE01-3425AD8F9D43</gtr:id><gtr:name>Telethon Kids Institute</gtr:name><gtr:address><gtr:line1>P.O. Box 855</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AFCF678A-5FC2-4D86-B376-12C1457C0F14"><gtr:id>AFCF678A-5FC2-4D86-B376-12C1457C0F14</gtr:id><gtr:name>Columbia University Medical Center</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Wellcome Trust Centre for Human Genetics</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A24FD58-D7D3-418E-BE01-3425AD8F9D43"><gtr:id>5A24FD58-D7D3-418E-BE01-3425AD8F9D43</gtr:id><gtr:name>Telethon Kids Institute</gtr:name><gtr:address><gtr:line1>P.O. Box 855</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AFCF678A-5FC2-4D86-B376-12C1457C0F14"><gtr:id>AFCF678A-5FC2-4D86-B376-12C1457C0F14</gtr:id><gtr:name>Columbia University Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/715F7D34-8517-4582-83B7-6E4C3A5F6EFA"><gtr:id>715F7D34-8517-4582-83B7-6E4C3A5F6EFA</gtr:id><gtr:firstName>Thomas</gtr:firstName><gtr:otherNames>Edward</gtr:otherNames><gtr:surname>Parks</gtr:surname><gtr:orcidId>0000-0002-1163-8654</gtr:orcidId><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100449"><gtr:id>036EC66E-6447-494C-9426-CC69CE437C78</gtr:id><gtr:title>Genetic Susceptibility to Rheumatic Heart Disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1100449</gtr:grantReference><gtr:abstractText>Rheumatic heart disease (RHD) results from an excessive response to common bacteria called either Streptococcus pyogenes or Group A Streptococcus. An excessive response to the bacteria, mediated by the immune system, our toolkit for fighting infection, leads to damage to heart valves, termed RHD. The consequences include heart failure, stroke and infective endocarditis (heart valve infection) and together kill at least 500 000 people worldwide each year, as many as breast cancer.

In areas of poverty and over-crowded living conditions, particularly in the developing world, both RHD and bacterial skin and throat infections are common. Only a fraction of individuals infected by the causative bacteria go on to develop RHD. Although environmental factors such as poverty play a part, I believe that differences in our genome, the inherited blueprint for our bodies, might play a role as has been shown to be the case in other diseases. To read the genome we will ask patients and volunteers for a blood sample and use technology that simultaneously reads variation at approximately 200 000 points. Knowledge of these differences might further understanding of the interaction between infection and immunity, and potentially generate approaches to vaccine development.</gtr:abstractText><gtr:technicalSummary>Background: Rheumatic heart disease (RHD) and its precursor acute rheumatic fever (ARF) result from an autoimmune response to infection with Streptococcus pyogenes (Group A Streptococcus, GAS). A significant cause of morbidity and mortality in the developing world, accounting for 500 000 deaths annually, half as many as malaria. Control of the disease is limited to antibiotic prophylaxis. Investment in research and development for ARF is only 0.4% of that for malaria and there is currently little prospect of developing a GAS vaccine effective in the developing world.

Objectives: To identify genetic variants associated with susceptibility to RHD allowing for potential confounders.

Study sample: Two thousand patients of Melanesian ethnicity from New Caledonia, Oceania, diagnosed with RHD by echocardiography (recruited to a cardiac imaging study planned by our collaborators) and an equivalent number of peer-nominated controls to be recruited from the same population will be consented for enrolment in genetic studies. Complete demographic and epidemiological data will be collected from each individual case and control as well as detailed clinical data including at a minimum a detailed echocardiographic study of all the cases.

Association study: Using a case-control association study approach, microarray technology will be used to genotype at least 200 000 single nucleotide polymorphisms in 1000 cases and 1000 controls. Putative associated alleles will be replicated in a further 1000 cases and 1000 controls using genotyping technology such as the Sequenom?s MassArray primer extension assay. This approach will give 80% power to detect significant association at allelic odds ratio of 1.5 or greater for alleles with a minor allele frequency of 10% or more at genome-wide significance (p-value = 5 x 10-7).

Implications: Rheumatic heart disease is unique example of an autoimmune process associated with a known specific pathogen. Therefore, with the potential to real genetic variation associated with susceptibility RHD, this study might further our understanding of the complex interaction between human genetics, susceptibility to infection and autoimmunity. In addition the results might generate new approaches to GAS vaccine development.</gtr:technicalSummary><gtr:fund><gtr:end>2015-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>186286</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Columbia University Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Division of Infectious Diseases</gtr:department><gtr:description>Genetics and Severe Streptococcal Infections in the UK</gtr:description><gtr:id>C40C1863-6DB2-42C6-9D01-97EF951D1E61</gtr:id><gtr:impact>Preparation including ethical approval for sample collection in UK.</gtr:impact><gtr:outcomeId>CMNicnjeSQK-2</gtr:outcomeId><gtr:partnerContribution>Public Health England have assisted with design of the research and will assist with recruitment of survivors. They provide expertise on the epidemiology of invasive streptococcal disease in the UK. Imperial College London provide expertise on invasive streptococcal disease and will pursue functional analysis of putative susceptibility variants.</gtr:partnerContribution><gtr:piContribution>This collaboration aims to establish a collection of DNA samples from survivors of invasive streptococcal disease and necrotising fasciitis and their family members with a view to genetic analysis by whole-exome sequencing analysis. I contribute to this network through having designed the research study, co-ordinating recruitment and conducting the genetic analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Telethon Kids Institute</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>International Rheumatic Heart Disease Meta-Analysis Consortium</gtr:description><gtr:id>DF0C363B-3F19-4031-BEB3-363CD6F3BCC0</gtr:id><gtr:impact>Preparing for genetics meta-analysis</gtr:impact><gtr:outcomeId>5463c24dd34605.29394980-2</gtr:outcomeId><gtr:partnerContribution>Contributing to analysis and collection of samples/data</gtr:partnerContribution><gtr:piContribution>Coordinating consortium
Leading analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Genetics and Severe Streptococcal Infections in the UK</gtr:description><gtr:id>6B35A81F-3383-4E83-BB71-CB2085CCB359</gtr:id><gtr:impact>Preparation including ethical approval for sample collection in UK.</gtr:impact><gtr:outcomeId>CMNicnjeSQK-1</gtr:outcomeId><gtr:partnerContribution>Public Health England have assisted with design of the research and will assist with recruitment of survivors. They provide expertise on the epidemiology of invasive streptococcal disease in the UK. Imperial College London provide expertise on invasive streptococcal disease and will pursue functional analysis of putative susceptibility variants.</gtr:partnerContribution><gtr:piContribution>This collaboration aims to establish a collection of DNA samples from survivors of invasive streptococcal disease and necrotising fasciitis and their family members with a view to genetic analysis by whole-exome sequencing analysis. I contribute to this network through having designed the research study, co-ordinating recruitment and conducting the genetic analysis.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cape Town</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>International Rheumatic Heart Disease Meta-Analysis Consortium</gtr:description><gtr:id>48B6081A-D3F9-4F71-9A65-B95D1D4E4C79</gtr:id><gtr:impact>Preparing for genetics meta-analysis</gtr:impact><gtr:outcomeId>5463c24dd34605.29394980-1</gtr:outcomeId><gtr:partnerContribution>Contributing to analysis and collection of samples/data</gtr:partnerContribution><gtr:piContribution>Coordinating consortium
Leading analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>PG/14/26/30509</gtr:fundingRef><gtr:id>1A9DA3AD-9082-4DA9-9F24-8A93390A6BF8</gtr:id><gtr:outcomeId>5463c2d2845e42.76608690</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>34000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sir Halley Stewart Trust Research Project Grant</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Sir Halley Stewart Trust</gtr:fundingOrg><gtr:id>37FCDB51-45CB-4F87-8961-08DD5A40C8AF</gtr:id><gtr:outcomeId>SyMF6arxYLw</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BMA Research Grants Programme</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>British Medical Association (BMA)</gtr:fundingOrg><gtr:fundingRef>Josephine Lansdell 2012</gtr:fundingRef><gtr:id>98AD6044-82BB-40D2-B21D-451BAC29C66B</gtr:id><gtr:outcomeId>kVzSG63GhfD</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ESCMID Research Grants</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>European Society of Clinical Microbiology and Infectious Diseases (ESCMID)</gtr:fundingOrg><gtr:id>3F84ADEE-C1FD-44B7-844F-AD3D70941AEE</gtr:id><gtr:outcomeId>mE3SBca8MEk</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Use of research by Fiji Ministry of Health Department of Non-Communicable Diseases</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>00D30580-F5D9-412C-9CB7-DDCAC4F1AAE2</gtr:id><gtr:outcomeId>CDD993Qy8WZ</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Prior to this project little research into genetic susceptibility to rheumatic heart disease had been conducted. We have established the world's largest collection of DNA samples from patients with rheumatic heart disease and healthy volunteers.</gtr:description><gtr:id>E614E050-F1D3-469D-8098-FA7759234761</gtr:id><gtr:impact>This has enabled initial steps towards studies of genetic susceptibility to rheumatic heart disease.</gtr:impact><gtr:outcomeId>LttAkr6PSZt</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Pacific Islands Rheumatic Heart Disease Network DNA Collection</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Little data is available pertaining to the epidemiology of rheumatic heart disease in developing countries. This database bringing together routine data for the period 2008-2012 from a patient information system, a database of death certificates, the national disease control programme's (NDCP) register, and information collected from echocardiography clinic registers permits estimates of prevalence, incidence, relative survival and rates of complications.</gtr:description><gtr:id>B0D23124-A057-4E4D-89CF-E1D526FEF837</gtr:id><gtr:impact>Preliminary findings from this research have been reported to the Fiji Ministry of Health to guide public health policy for control of rheumatic heart disease. A summary of the findings have also been shared with the Global Burden of Disease Project who will use the information to update estimates of global burden of rheumatic heart disease.</gtr:impact><gtr:outcomeId>GMMu4jV8ky3</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Fiji Rheumatic Heart Disease Data-Linkage study</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>EE3A738B-6A6C-4BE2-831E-8DB3685B7F6F</gtr:id><gtr:title>Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c58ff4bb9aaa16205e33269447f852fb"><gtr:id>c58ff4bb9aaa16205e33269447f852fb</gtr:id><gtr:otherNames>Parks T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a35db15413556.89709797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E91A1CCB-A42C-4A4D-92F9-2A0687C8F689</gtr:id><gtr:title>Invasive streptococcal disease: a review for clinicians.</gtr:title><gtr:parentPublicationTitle>British medical bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c58ff4bb9aaa16205e33269447f852fb"><gtr:id>c58ff4bb9aaa16205e33269447f852fb</gtr:id><gtr:otherNames>Parks T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1420</gtr:issn><gtr:outcomeId>56dab7b732f521.41198237</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E27BBE57-FF9A-4263-ADCF-86BD77A5DD5C</gtr:id><gtr:title>Clinical outcomes for young people with screening-detected and clinically-diagnosed rheumatic heart disease in Fiji.</gtr:title><gtr:parentPublicationTitle>International journal of cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99c0599d48bbcc82f5f38653e59f59b7"><gtr:id>99c0599d48bbcc82f5f38653e59f59b7</gtr:id><gtr:otherNames>Engelman D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0167-5273</gtr:issn><gtr:outcomeId>5aa6ef823b6377.68806041</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25908EDD-E101-484B-BA15-55A1D76AC624</gtr:id><gtr:title>Rheumatic Heart Disease-Attributable Mortality at Ages 5-69 Years in Fiji: A Five-Year, National, Population-Based Record-Linkage Cohort Study.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c58ff4bb9aaa16205e33269447f852fb"><gtr:id>c58ff4bb9aaa16205e33269447f852fb</gtr:id><gtr:otherNames>Parks T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>56dab7b6dac861.41604640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C56E913-9F7F-4677-A467-AF776E70F0D7</gtr:id><gtr:title>Prevalence of Rheumatic Heart Disease in the Pacific: From Subclinical to Symptomatic Heart Valve Disease.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69d7cdda10a1fb29a6e78902c86ade98"><gtr:id>69d7cdda10a1fb29a6e78902c86ade98</gtr:id><gtr:otherNames>Mirabel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>5aa6ef82b817a6.64473550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C211F2EC-C359-410A-8D8E-B087B8DDD346</gtr:id><gtr:title>Newly diagnosed rheumatic heart disease among indigenous populations in the Pacific.</gtr:title><gtr:parentPublicationTitle>Heart (British Cardiac Society)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69d7cdda10a1fb29a6e78902c86ade98"><gtr:id>69d7cdda10a1fb29a6e78902c86ade98</gtr:id><gtr:otherNames>Mirabel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1355-6037</gtr:issn><gtr:outcomeId>56dab7b70ebb22.60967234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6A2EE47-1DBB-460E-B984-F21F3ECE741D</gtr:id><gtr:title>ASO titer or not? When to use streptococcal serology: a guide for clinicians.</gtr:title><gtr:parentPublicationTitle>European journal of clinical microbiology &amp; infectious diseases : official publication of the European Society of Clinical Microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c58ff4bb9aaa16205e33269447f852fb"><gtr:id>c58ff4bb9aaa16205e33269447f852fb</gtr:id><gtr:otherNames>Parks T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0934-9723</gtr:issn><gtr:outcomeId>56dab7b78325a5.76707350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0340C183-E122-4D49-B012-86CE48ABECE7</gtr:id><gtr:title>Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de5213129f11c0cb3d7e2091308bbfdb"><gtr:id>de5213129f11c0cb3d7e2091308bbfdb</gtr:id><gtr:otherNames>Rautanen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>56dab7b75853b5.37931330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66194211-2DB2-4A58-8A4E-E6CD00CC1B8D</gtr:id><gtr:title>Adherence to secondary antibiotic prophylaxis for patients with rheumatic heart disease diagnosed through screening in Fiji.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99c0599d48bbcc82f5f38653e59f59b7"><gtr:id>99c0599d48bbcc82f5f38653e59f59b7</gtr:id><gtr:otherNames>Engelman D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>5aa6ef8288c339.67177806</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9F97E20-7D9C-4DAF-9ECE-2C26578B86DE</gtr:id><gtr:title>IFITM3 and susceptibility to respiratory viral infections in the community.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7554e2e7fa6172275cbb2d59177c75eb"><gtr:id>7554e2e7fa6172275cbb2d59177c75eb</gtr:id><gtr:otherNames>Mills TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_23788_28_23997235</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100449</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>